

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 September 2023 (28.09.2023)



(10) International Publication Number
WO 2023/180549 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 14/74 (2006.01)
C07K 14/705 (2006.01) A61P 25/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2023/057684

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:

24 March 2023 (24.03.2023)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22164161.6 24 March 2022 (24.03.2022) EP

(71) Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT
WÜRZBURG [DE/DE]; Sanderring 2, 97070 Würzburg
(DE).

(72) Inventors: BRUTTEL, Valentin; Luitpoldquelle 10,
97080 Würzburg (DE). WISCHHUSEN, Jörg; Leut-
fresserweg 14a, 97082 Würzburg (DE). JAYARAM,
Shriya Mamatha; Versbacherstr. 107, 97078 Würzburg
(DE). AHSAN, Fadhil; Elbersfelder Str. 30, 10555 Berlin
(DE).

(74) Agent: HOFFMANN EITLE PATENT- UND
RECHTSANWÄLTE PARTMBB; Arabellastraße 30,
81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: MHC IB-MEDIATED AQUAPORIN 4 (AQP4)-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR
NMO

(57) Abstract: The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC)
molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of neuromyelitis optica (NMO).
The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-
classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical
compositions comprising the same, as well as their uses for treating neuromyelitis optica (NMO).

WO 2023/180549 A1